An ongoing clinical trial is designed for the evaluation of efficiency and side effects of anti-CD38 CAR T-cells in relapsed B- ALL after CD19/CD22 CAR T-cell therapy [81]. Here, CD22 is linked to acute lymphoblastic leukemia.